US equities |
MU $983.23 ▲+5.86% META $612.49 ▼-1.24% NVDA $215.38 ▼-1.17% GOOGL $324.89 ▲+1.34% MSFT $531.01 ▼-0.06% TSLA $404.22 ▼-0.80% SPCX $145.23 ▼-2.25% SNDK $1,404.77 ▲+7.66%
FinancialContent

Articles published by Merck & Co., Inc.

< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
News headline image
Merck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infection
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Receives Positive CHMP Opinion for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Infants and Children
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Five-Year Data for Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Sustained Survival Benefit Versus Chemotherapy Alone in Two Studies for Metastatic Non-Small Cell Lung Cancer (NSCLC)
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck and Eisai Present Results From Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
LYNPARZA® (olaparib) in Combination With Bevacizumab, and as Monotherapy, Demonstrates Clinically Meaningful Long-Term Survival in Certain Patients With First-Line Advanced Ovarian Cancer in Exploratory Analyses of Two Phase 3 Trials
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Reports Strong Progress in ESG Focus Areas
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck to Present New Data at ESMO 2022 Congress From Its Broad Oncology Portfolio and Promising Pipeline, Demonstrating Commitment to Improving Long-Term Survival in Multiple Types of Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
LYNPARZA® (olaparib) Approved in Japan as Adjuvant Treatment for Patients With BRCA-Mutated, HER2-Negative High Recurrent Risk Breast Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Receives Fast Track Designation from the U.S. FDA for MK-2060, an Investigational Anticoagulant Therapy
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
FDA Accepts Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone for Patients With Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck and Orna Therapeutics Collaborate to Advance Orna’s Next Generation of RNA Technology
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
LYNPARZA® (olaparib) Approved in the EU as Adjuvant Treatment for Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck and Eisai Provide Update on Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Provides Update on Phase 3 KEYNOTE-921 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Announces Second-Quarter 2022 Financial Results
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Announces Fourth-Quarter 2022 Dividend
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Provides Update on Phase 3 KEYNOTE-412 Trial in Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck and Orion Announce Global Collaboration for the Development and Commercialization of ODM-208, an Investigational Steroid Synthesis Inhibitor for the Treatment of Metastatic Castration-Resistant Prostate Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Announces the Launch of the Merck Digital Sciences Studio to Help Healthcare Startups Quickly Bring their Innovations to Market
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck to Hold Second-Quarter 2022 Sales and Earnings Conference Call July 28
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
LYNPARZA® (olaparib) Receives Positive Opinion From EU CHMP as Adjuvant Treatment for Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent Patients (≥12 Years of Age) With Stage IIB or IIC Melanoma Following Complete Resection
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
CDC’s ACIP Unanimously Votes to Provisionally Recommend Use of Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) as an Option for Pneumococcal Vaccination in Infants and Children
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
U.S. FDA Approves Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Infants and Children
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Results From Phase 3 PROpel Trial of LYNPARZA® (olaparib) Plus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer Published in NEJM Evidence
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Announces that Chirfi Guindo will Lead Marketing for Merck Human Health
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Presents Positive Results from Phase 1/2 Study Evaluating V116, the Company’s Investigational Pneumococcal Conjugate Vaccine for Adults
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Stage IB (≥4 centimeters)-IIIA Non-Small Cell Lung Cancer Following Complete Surgical Resection
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck to Participate in the 2022 Goldman Sachs 43rd Annual Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >